Two years ago, I interviewed Alex Kostic, who was then a postdoctoral fellow at the Broad Institute of MIT and Harvard exploring the microbiome’s…
In October, JDRF took the organization’s first step into the burgeoning world of DIY diabetes technology when it announced a new initiative to…
November 14 was World Diabetes Day, and organizations around the world brought attention to the disease in various ways. JDRF in the U.S. highlighted…
With Congress due to leave for August recess at the end of this week, those following Republicans’ efforts to replace Obamacare with Trumpcare…
Imagine a molecular container where the building blocks are glued together with a substance that’s sensitive to glucose: when glucose levels…
The science journalist Gary Taubes starts his book The Case Against Sugar with the following argument: we live in a society where two conditions…
This past summer my daughter, Bisi, who has Type 1 diabetes, and I were hanging out on the beach on Block Island when she spotted a man walking by with…
A couple of weeks ago I sat down with Dr. Francisco Quintana, who runs a lab at Brigham and Women’s Hospital in Boston focused on finding new treatments…
The initial study, which will start enrolling next year, will involve about ten patients, who will have the stem-cell derived beta cells injected into their forearms, in the hopes that the cells will start producing insulin within the body.
JDRF, partnered with Sanofi, the company that manufactures Lantus among other insulins, recently pledged up to $4.6 million to support research into four different efforts to design a glucose-responsive insulin.